


Enrollment chart



Not started **Ongoing** Completed

**Screened**  
Screenout rate: 19% **218**

**Enrolled**  
Enrollment rate: 0.19 **175**


“You said **blue** would cross the **red**, and it did.”

SVP of Clinical Operations

Year 2022 to be added  
(mCRPC approval)

# PSI Oncology Timeline

## KEY DRUG APPROVALS



## **PULMONARY**

Non-small cell lung cancer  
Small cell lung cancer  
Adenocarcinoma/other

## **BREAST CANCER**

### **GI**

Colorectal cancer  
Gastric cancer  
Pancreatic cancer  
Esophageal cancer  
Hepatocellular carcinoma  
GEP-NET

### **UROLOGY**

Bladder cancer  
Prostate cancer  
Renal cell carcinoma

### **NEUROLOGY**

Brain metastases  
Leptomeningeal disease  
Primary central nervous system lymphoma

## **GYNECOLOGIC CANCERS**

Ovarian cancer  
Endometrial carcinoma

## **SOLID TUMORS**

## **HEMATOLOGIC MALIGNANCIES**

Lymphomas  
Leukemias  
Multiple myeloma  
Myelodysplastic syndrome  
Thrombotic microangiopathy

## **MYELOPROLIFERATIVE NEOPLASMS**

Polycythemia vera  
Myelofibrosis  
Essential thrombocythemia

## **HEAD & NECK CANCER**

## **MELANOMA**

## **SUPPORTIVE CARE**

CINV  
Chemo-induced neutropenia  
Chemo-induced neurotoxicity  
Chemo-induced diarrhea  
Chemo-induced myelosuppression  
Cancer-related pain  
Cancer-related cachexia  
Bone metastases  
Radiation-induced mucositis  
Oral Mucositis in head&neck cancer

## **RARE CANCERS**

Ewing family of tumors or rhabdomyosarcoma  
Dedifferentiated liposarcoma

\* Includes pediatric studies